Literature DB >> 25870793

Epidermal growth factor receptor in non-small cell lung cancer.

Charles N Prabhakar1.   

Abstract

Following the identification of a group of patients in the initial tyrosine kinase inhibitor (TKI) trials for lung cancer, there has been detailed focus on which patients may benefit from inhibitor therapy. This article reviews the background, genetics and prevalence of epidermal growth factor mutations in non-small cell lung cancer (NSCLC). Additionally, the prevalence in unselected patients is compared against various other reviews.

Entities:  

Keywords:  Lung neoplasms; carcinoma; epidermal growth factor; non-small cell lung cancer (NSCLC); receptor

Year:  2015        PMID： 25870793      PMCID： PMC4384217          DOI： 10.3978/j.issn.2218-6751.2015.01.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  63 in total

1.  Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

Authors:  Tae-Jung Kim; Chan Kwon Park; Chang Dong Yeo; Kihoon Park; Chin Kook Rhee; Jusang Kim; Seung Joon Kim; Sang Haak Lee; Kyo-Young Lee; Hyoung-Kyu Yoon
Journal:  J Surg Oncol       Date:  2014-05-29       Impact factor: 3.454

2.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

3.  High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Authors:  Ping-Li Sun; Hyesil Seol; Hyun Ju Lee; Seol Bong Yoo; Hyojin Kim; Xianhua Xu; Sanghoon Jheon; Choon-Taek Lee; Jong-Suk Lee; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 4.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

5.  Frequency of and variables associated with the EGFR mutation and its subtypes.

Authors:  Tomoaki Tanaka; Masaru Matsuoka; Akihisa Sutani; Akihiko Gemma; Makoto Maemondo; Akira Inoue; Shoji Okinaga; Makoto Nagashima; Satoshi Oizumi; Kazutsugu Uematsu; Yoshiaki Nagai; Gaku Moriyama; Hitoshi Miyazawa; Kenji Ikebuchi; Satoshi Morita; Kunihiko Kobayashi; Koichi Hagiwara
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

Review 6.  The role of EGFR inhibitors in nonsmall cell lung cancer.

Authors:  Fortunato Ciardiello; Ferdinando De Vita; Michele Orditura; Giampaolo Tortora
Journal:  Curr Opin Oncol       Date:  2004-03       Impact factor: 3.645

7.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Epidermal growth factor-receptor-protein kinase interactions.

Authors:  S Cohen; G Carpenter; L King
Journal:  Prog Clin Biol Res       Date:  1981

Review 9.  Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis.

Authors:  A Parsons; A Daley; R Begh; P Aveyard
Journal:  BMJ       Date:  2010-01-21

10.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Authors:  J-Y Douillard; G Ostoros; M Cobo; T Ciuleanu; R McCormack; A Webster; T Milenkova
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more
  27 in total

1.  Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.

Authors:  Arsham Banisadr; Yaghoub Safdari; Anvarsadat Kianmehr; Mahdieh Pourafshar
Journal:  Hum Vaccin Immunother       Date:  2017-12-21       Impact factor: 3.452

Review 2.  Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.

Authors:  Michael J Donovan; Carlos Cordon-Cardo
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

Review 3.  Role of epidermal growth factor receptor in lung cancer and targeted therapies.

Authors:  Tie-Cheng Liu; Xin Jin; Yan Wang; Ke Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

4.  Antiproliferative Activity of a New Quinazolin-4(3H)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer.

Authors:  Ji Yun Lee; Huarong Yang; Donghwa Kim; Kay Zin Kyaw; Ruoci Hu; Yanhua Fan; Sang Kook Lee
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-02

5.  Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.

Authors:  Hui-Xi Zou; Yu-Feng Zhang; Da-Fang Zhong; Yong Jiang; Fei Liu; Qian-Yu Zhao; Zhong Zuo; Yi-Fan Zhang; Xiao-Yu Yan
Journal:  Acta Pharmacol Sin       Date:  2021-11-17       Impact factor: 7.169

Review 6.  Influence of estrogen in non-small cell lung cancer and its clinical implications.

Authors:  Vianey Rodriguez-Lara; Juan-Manuel Hernandez-Martinez; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 7.  The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis.

Authors:  Satoru Ochiai; Yoshihito Nomoto; Yui Watanabe; Yasufumi Yamashita; Yutaka Toyomasu; Tomoko Kawamura; Akinori Takada; Hajime Sakuma
Journal:  J Radiat Res       Date:  2016-08-16       Impact factor: 2.724

8.  Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.

Authors:  Bing Wang; Hong Jiang; Limin Wang; Xueqin Chen; Kan Wu; Shirong Zhang; Shenglin Ma; Bing Xia
Journal:  Oncol Lett       Date:  2017-03-20       Impact factor: 2.967

Review 9.  An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment.

Authors:  Vianey Rodriguez-Lara; Maria Rosa Avila-Costa
Journal:  Front Med (Lausanne)       Date:  2021-05-17

Review 10.  Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Authors:  Young Kwang Chae; Ayush Arya; Lauren Chiec; Hiral Shah; Ari Rosenberg; Sandip Patel; Kirtee Raparia; Jaehyuk Choi; Derek A Wainwright; Victoria Villaflor; Massimo Cristofanilli; Francis Giles
Journal:  Oncotarget       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.